ストックスクリーナーアプリを入手
252.47
0.62%
1.55
アフターアワーズ：
252.00
-0.47
-0.19%
前日終値:
$250.92
開ける：
$252.92
24時間の取引高:
590.91K
Relative Volume:
0.58
時価総額：
$36.85B
収益：
$5.26B
当期純損益:
$1.44B
株価収益率:
25.84
EPS:
9.7713
ネットキャッシュフロー:
$1.76B
1週間 パフォーマンス:
+3.13%
1か月 パフォーマンス:
+2.41%
6か月 パフォーマンス:
-1.37%
1年 パフォーマンス:
+6.90%
1日の値動き範囲:
$250.18
$253.81
1週間の範囲:
$242.54
$253.81
52週間の値動き範囲:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
252.47 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
586.24 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.75 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.13 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
40.52 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
How ResMed Inc. stock performs in easing cyclesIndex Update & Reliable Intraday Trade Alerts - ulpravda.ru
Resmed Insider Sold Shares Worth $497,660, According to a Recent SEC Filing - marketscreener.com
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com UK
Resmed director Farrell sells $497k in shares - Investing.com
SG Americas Securities LLC Acquires 47,758 Shares of ResMed Inc. $RMD - MarketBeat
Robeco Institutional Asset Management B.V. Sells 11,596 Shares of ResMed Inc. $RMD - MarketBeat
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsWeekly Trend Summary & Weekly Return Optimization Plans - ulpravda.ru
Will ResMed Inc. stock gain from lower inflationJuly 2025 Catalysts & Expert Curated Trade Setups - ulpravda.ru
Why ResMed Inc. (RME) stock is listed among top recommendations2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
EV Market: How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsPortfolio Return Report & Pattern Based Trade Signal System - ulpravda.ru
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Resmed Sets January 29 Date to Unveil Q2 FY2026 Results - TipRanks
ResMed CEO Michael Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - The Manila Times
Dow Theory LettersResmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - FinancialContent
Resmed Insider Sold Shares Worth $1,240,065, According to a Recent SEC Filing - MarketScreener
Will ResMed Inc. stock deliver stable dividendsJuly 2025 Action & Verified Short-Term Plans - ulpravda.ru
How ResMed Inc. (RME) stock performs during market turbulenceQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Is ResMed Inc. (RME) stock protected from inflationEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
An excellent week for ResMed Inc.'s (NYSE:RMD) institutional owners who own 69% as one-year returns inch higher - Yahoo Finance
Resmed Receives FDA Clearance for AI-Personalized CPAP Mask Settings - San Diego Business Journal
Is This the Right Time to Add Resmed Stock to Your Portfolio? - TradingView — Track All Markets
ResMed Director Peter Farrell Plans Additional Insider Share Sale Under Rule 144 - TipRanks
ResMed CFO Sells Small Block of Shares Under Pre-Arranged Trading Plan - TipRanks
Insider at company (NYSE: RMD) files Rule 144 to sell 2,000 shares - Stock Titan
RMD (RMD) insider Michael Farrell files to sell 4,991 common shares - Stock Titan
Will ResMed Inc. stock attract more institutional investorsVolume Analysis Techniques & Outperform With Our Smart Trading Calculator - ulpravda.ru
The Truth About ResMed Inc: Sleep Tech Darling or Overhyped Dinosaur? - AD HOC NEWS
ResMed stock in focus: sleep-tech leader tests investor conviction after choppy start to the year - AD HOC NEWS
EBIT per share of Resmed Inc. – OTC:RSMDF - TradingView — Track All Markets
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight - GlobeNewswire Inc.
ResMed updates CDI and share structure for December 2025 - MSN
Asset Management One Co. Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
What you need to know ahead of ResMed's earnings release - MSN
ResMed Updates CDI and Share Structure for December 2025 - TipRanks
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed (RMD) CFO discloses 1,000-share planned stock sale in Form 4 - Stock Titan
ResMed Officer Brett Sandercock Discloses Planned Sale of 1,000 Shares Under Trading Plan - TipRanks
ResMed (NYSE:RMD) General Counsel Michael Rider Sells 50 Shares - MarketBeat
ResMed (RMD) Valuation Check As Investors Await Fiscal Q2 Earnings Update - Sahm
ResMed Inc (RMD) general counsel reports 50-share insider stock sale - Stock Titan
ResMed Q2 2026 Earnings Preview: EPS Growth Forecast & Analyst Rating | BarchartNews and Statistics - IndexBox
ResMed Inc. $RMD Shares Sold by TriaGen Wealth Management LLC - MarketBeat
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
0.61%
0.11%
大文字化:
|
ボリューム (24 時間):